Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01387230 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
NCT01387230 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 206 participants.
The verdict
NCT01387230, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
Study Summary
The purpose of this study is to assess if 12 weeks' treatment with GSK573719 Inhalation Powder is safe and effective compared with placebo or no active drug intake, when administered once-daily in subjects with Chronic Obstructive Pulmonary Disease (COPD).
Interventions
- OTHER Placebo
- DRUG GSK573719
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2011-07-01 |
| Est. Completion | 2012-02-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01387230
The ClinicalTrials.gov registry entry for NCT01387230 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01387230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01387230 about?
NCT01387230 is a clinical study titled "Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD". The purpose of this study is to assess if 12 weeks' treatment with GSK573719 Inhalation Powder is safe and effective compared with placebo or no active drug intake, when administered once-daily in subjects with Chronic Obstructive Pulmonary Disease (COPD).
What is the current status of trial NCT01387230?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2011-07-01. Estimated completion is 2012-02-13.
What interventions are being tested in trial NCT01387230?
The interventions under investigation include: Placebo (OTHER), GSK573719 (DRUG).
Who is sponsoring clinical trial NCT01387230?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.